<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="155">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 14, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02243618</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0381</org_study_id>
    <nct_id>NCT02243618</nct_id>
  </id_info>
  <brief_title>The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic submucosal dissection (ESD) is an advanced technique that enables en bloc
      resection of superficial tumors in the gastrointestinal tract. ESD, however, is a
      time-consuming procedure that requires a high level of endoscopic skill to achieve a
      desirable oncologic outcome. Several procedure-related complications may occur after ESD.
      Especially, iatrogenic ulcer bleeding after ESD can be a concern for both endoscopists and
      patients. In order to reduce the bleeding rate, proton pump inhibitors (PPIs) are
      administered after ESD. In addition, ulcer protective agents such as rebamipide can be added
      to PPIs for accelerating ulcer healing. We aimed to evaluate the efficacy of polaprezinc for
      healing of iatrogenic ulcer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ulcering healing rate</measure>
    <time_frame>4 weeks after the ESD</time_frame>
    <safety_issue>No</safety_issue>
    <description>Healing rate of the iatrogenic ulcer according to the type of ulcer protective agents (polaprezinc vs. rebamipide).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scarring change rate</measure>
    <time_frame>4 weeks after the ESD</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scarring change rate of the iatrogenic ulcer according to the type of ulcer protective agents (polaprezinc vs. rebamipide).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Gastric Adenoma and Early Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Rebamipide group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Polaprezinc group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polaprezinc</intervention_name>
    <description>Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.</description>
    <arm_group_label>Polaprezinc group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide</intervention_name>
    <description>Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.</description>
    <arm_group_label>Rebamipide group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age, between 19 and 79

          2. Patients with gastric adenoma or early gastric cancer

          3. Patients with ECOG-PS 0 or 1

          4. Patients with adequate renal function

          5. Patients with adequate hepatic function

          6. Patients with adequate bone marrow function

        Exclusion Criteria:

          1. Patients who has taken the medications for ulcer including PPIs, H2 blockers, and
             mucosal protective agents within 3 months prior to the ESD.

          2. Patients who has taken steroid or NSAIDswithin 3 months prior to the ESD.

          3. Patients who has undergone gastrostomy

          4. Patients with allergy for pantoprazole, polaprezinc, or rebamipide.

          5. Pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Chul Park, MD</last_name>
    <phone>82-2-2228-2272</phone>
    <email>junchul75@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sevrance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>September 15, 2014</lastchanged_date>
  <firstreceived_date>September 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polaprezinc</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
